In many cells and specially in muscle, mitochondria form elongated filaments or a branched reticulum. We show that Mfn2 (mitofusin 2), a mitochondrial membrane protein that participates in mitochondrial fusion in mammalian cells, is induced during myogenesis and contributes to the maintenance and operation of the mitochondrial network. Repression of Mfn2 caused morphological and functional fragmentation of the mitochondrial network into independent clusters. Concomitantly, repression of Mfn2 reduced glucose oxidation, mitochondrial membrane potential, cell respiration, and mitochondrial proton leak. We also show that the Mfn2-dependent mechanism of mitochondrial control is disturbed in obesity by reduced Mfn2 expression. In all, our data indicate that Mfn2 expression is crucial in mitochondrial metabolism through the maintenance of the mitochondrial network architecture, and reduced Mfn2 expression may explain some of the metabolic alterations associated with obesity.
We have identified a new human cDNA, L-amino acid transporter-2 (LAT-2), that induces a system L transport activity with 4F2hc (the heavy chain of the surface antigen 4F2, also named CD98) in oocytes. Human LAT-2 is the fourth member of the family of amino acid transporters that are subunits of 4F2hc. The amino acid transport activity induced by the co-expression of 4F2hc and LAT-2 was sodium-independent and showed broad specificity for small and large zwitterionic amino acids, as well as bulky analogs (e.g. BCH (2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid)). This transport activity was highly trans-stimulated, suggesting an exchanger mechanism of transport. Expression of tagged N-myc-LAT-2 alone in oocytes did not induce amino acid transport, and the protein had an intracellular location. Co-expression of N-myc-LAT-2 and 4F2hc gave amino acid transport induction and expression of N-myc-LAT-2 at the plasma membrane of the oocytes. These data suggest that LAT-2 is an additional member of the family of 4F2 light chain subunits, which associates with 4F2hc to express a system L transport activity with broad specificity for zwitterionic amino acids. Human LAT-2 mRNA is expressed in kidney >>> placenta > > brain, liver > spleen, skeletal muscle, heart, small intestine, and lung. Human LAT-2 gene localizes at chromosome 14q11.2-13 (13 cR or ϳ286 kb from marker D14S1349). The high expression of LAT-2 mRNA in epithelial cells of proximal tubules, the basolateral location of 4F2hc in these cells, and the amino acid transport activity of LAT-2 suggest that this transporter contributes to the renal reabsorption of neutral amino acids in the basolateral domain of epithelial proximal tubule cells.Last year, three amino acid transporter cDNAs (LAT-1, y ϩ LAT-1, and y ϩ LAT-2) 1 were identified as subunits of the heavy chain of the cell surface antigen 4F2 (4F2hc, also named CD98) (1-3). These subunits co-express amino acid transport activity with 4F2hc in oocytes (i.e. system L for LAT-1, and system y ϩ L for y ϩ LAT-1 and y ϩ LAT-2) (1-4). The role of this family of proteins in amino acid transport has recently been demonstrated by the fact that mutations in the y ϩ LAT-1 gene cause lysinuric protein intolerance, an inherited amino aciduria due to a defective renal reabsorption mechanism of dibasic amino acids (5, 6). The structural and functional similarities between 4F2hc and its homologous protein rBAT suggest that a member of this family of subunits might be the subunit of rBAT needed to fully express the amino acid transport system b o,ϩ activity (reviewed in Refs. 7 and 8). After the identification of rBAT as the Type I cystinuria gene (9), this subunit is a good candidate for non-Type I cystinuria (7). A search throughout gene data bases suggests that there may be as many as four new human members of the family of subunits of 4F2hc and rBAT.Kanai and co-workers (1) identified rat LAT-1 (also known as TA1) by co-expression cloning with 4F2hc in oocytes. The coexpressed transport activity shows clear characteristic...
We have identified a new human cDNA (y ؉ L amino acid transporter-1 (y ؉ LAT-1)) that induces system y ؉ L transport activity with 4F2hc (the surface antigen 4F2 heavy chain) in oocytes. Human y ؉ LAT-1 is a new member of a family of polytopic transmembrane proteins that are homologous to the yeast high affinity methionine permease MUP1. Other members of this family, the Xenopus laevis IU12 and the human KIAA0245 cDNAs, also co-express amino acid transport activity with 4F2hc in oocytes, with characteristics that are compatible with those of systems L and y ؉ L, respectively. y ؉ LAT-1 protein forms a Ϸ135-kDa, disulfide bond-dependent heterodimer with 4F2hc in oocytes, which upon reduction results in two protein bands of Ϸ85 kDa (i.e. 4F2hc) and Ϸ40 kDa (y ؉ LAT-1). Mutation of the human 4F2hc residue cysteine 109 (Cys-109) to serine abolishes the formation of this heterodimer and drastically reduces the coexpressed transport activity. These data suggest that y ؉ LAT-1 and other members of this family are different 4F2 light chain subunits, which associated with 4F2hc, constitute different amino acid transporters. Human y ؉ LAT-1 mRNA is expressed in kidney > > peripheral blood leukocytes > > lung > placenta ؍ spleen > small intestine. The human y ؉ LAT-1 gene localizes at chromosome 14q11.2 (17cR Ϸ 374 kb from D14S1350), within the lysinuric protein intolerance (LPI) locus (Lauteala, T., Sistonen, P., Savontaus, M. L., Mykkanen, J., Simell, J., Lukkarinen, M., Simmell, O., and Aula, P. (1997) Am. J. Hum. Genet. 60, 1479 -1486). LPI is an inherited autosomal disease characterized by a defective dibasic amino acid transport in kidney, intestine, and other tissues. The pattern of expression of human y ؉ LAT-1, its coexpressed transport activity with 4F2hc, and its chromosomal location within the LPI locus, suggest y ؉ LAT-1 as a candidate gene for LPI.rBAT and 4F2hc are homologous proteins that induce amino acid transport in Xenopus oocytes (1, 2). These two proteins are slightly hydrophobic, which prompted the hypothesis that rBAT and 4F2hc are subunits or modulators of the corresponding amino acid transporter. This has been supported by several indirect observations: (i) rBAT and 4F2hc are involved in the induction of several activities in Xenopus oocytes (3-6); (ii) these two proteins can be immunodetected or immunoprecipitated as complexes of Ϸ125 kDa in the absence of reducing agents and as two proteins of Ϸ85 kDa (4F2hc or rBAT) and Ϸ40 kDa in the presence of reducing agents (7-9); and (iii) in oocytes, there is a dissociation between the expression of 4F2hc and rBAT at the plasma membrane and the induction of system y ϩ L and b 0,ϩ activity, respectively, indicating that this expression is limited by an endogenous factor (10, 11). We have recently provided new evidence that the amino acid transport system y ϩ L has a heterodimeric structure (11). Thus, we have shown that the y ϩ L activity induced in oocytes by a cysteineless mutant of human 4F2hc is also inactivated by membraneimpermeant thiol-specific ...
Incubation of bone marrow macrophages with lipopolysaccharide (LPS) or interferon gamma (IFN gamma) blocks macrophage proliferation. LPS treatment or M-CSF withdrawal arrests the cell cycle at early G1 and induces apoptosis. Treatment of macrophages with IFN gamma stops the cell cycle later, at the G1/S boundary, induces p21Waf1, and does not induce apoptosis. Moreover, pretreatment of macrophages with IFN gamma protects from apoptosis induced by several stimuli. Inhibition of p21Waf1 with antisense oligonucleotides or using KO mice shows that the induction of p21Waf1 by IFN gamma mediates this protection. Thus, IFN gamma makes macrophages unresponsive to apoptotic stimuli by inducing p21Waf1 and arresting the cell cycle at the G1/S boundary. Therefore, the cells of the innate immune system could only survive while they were functionally active.
Cystinuria (MIM 220100) is a common recessive disorder of renal reabsorption of cystine and dibasic amino acids. Mutations in SLC3A1, encoding rBAT, cause cystinuria type I (ref. 1), but not other types of cystinuria (ref. 2). A gene whose mutation causes non-type I cystinuria has been mapped by linkage analysis to 19q12-13.1 (Refs 3,4). We have identified a new transcript, encoding a protein (bo, +AT, for bo,+ amino acid transporter) belonging to a family of light subunits of amino acid transporters, expressed in kidney, liver, small intestine and placenta, and localized its gene (SLC7A9) to the non-type I cystinuria 19q locus. Co-transfection of bo,+AT and rBAT brings the latter to the plasma membrane, and results in the uptake of L-arginine in COS cells. We have found SLC7A9 mutations in Libyan-Jews, North American, Italian and Spanish non-type I cystinuria patients. The Libyan Jewish patients are homozygous for a founder missense mutation (V170M) that abolishes b o,+AT amino-acid uptake activity when co-transfected with rBAT in COS cells. We identified four missense mutations (G105R, A182T, G195R and G295R) and two frameshift (520insT and 596delTG) mutations in other patients. Our data establish that mutations in SLC7A9 cause non-type I cystinuria, and suggest that bo,+AT is the light subunit of rBAT.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.